This cohort study describes 5-year outcomes following a de-escalated 30-Gy elective nodal irradiation regimen during definitive concurrent chemoradiotherapy among patients with human papillomavirus–associated oropharyngeal carcinoma.
A. Safavi, E. Dee, C. Tsai et al.· JAMA Oncology· 0 citations
CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. The primary endpoint was 24-month...
N. Shaverdian, M. Offin, N. Toumbacaris et al.· Nature Communications· 0 citations
This retrospective study compared the efficacy and toxicity of concurrent triweekly versus weekly cisplatin in patients with previously untreated, biopsy-proven NPC who received definitive CRT followed by adjuvant chemotherapy. Patients with distant metastasis, Karnofsky Performance Status < 80, induction chemotherapy,...
Hao-Shen Cheng, Irini Yacoub, W. Wong et al.· International Journal of Can...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.